A attainable co-appearance of anticardiolipin (aCL), anti-β2-glycoprotein I (anti-β2-GPI), anti-prothrombin (aPT) and anti-annexin V (aANXV) antibodies of IgG, IgM and IgA class have been studied in 58 sufferers with SLE alone and 32 sufferers APS within the view of rational laboratory diagnostics.
The presence of anti-phospholipid antibodies (aPL) have been outlined by our in-house ELISA strategies. Out of 17 aCL destructive SLE sufferers 6 had different antigenically outlined aPL antibodies. In 13 sufferers solely IgA however not IgG and IgM anti-β2GPI have been detected. Totally different mixtures of aPL subsets have been equally distributed in APS and SLE teams.
The prevalence of aANXV have been comparable in APS and SLE sufferers which was not the case with different aPL. Our findings assist the concept of measuring further subsets of aPL (aPT and aANXV) in unclear instances. IgA (both aCL or anti-β2-GPI) improved neither the diagnostic specificity nor diagnostic sensitivity, however solely elevated the frequency of the full anti-β2-GPI.
Anti-annexin V IgG and IgM antibodies in sickle cell illness sufferers with vaso-occlusive disaster.
Vaso-occlusive disaster (VOC) is a big explanation for morbidity and mortality in sickle cell anemia (SCA) sufferers; nevertheless, its mechanisms are poorly understood. In view of their prothrombotic nature, we hypothesized that SCA-associated VOC could also be because of the presence of anti-annexin V antibodies. Anti-annexin V antibodies have been measured with ELISA in 177 VOC and 81 steady-state SCA sufferers.
Anti-annexin V IgM and IgG concentrations have been considerably larger in VOC sufferers than in steady-state sufferers and have been related to elevated VOC danger. After categorizing anti-annexin V antibodies, the adjusted odds ratio elevated because the percentile worth elevated. Monovariate logistic regression evaluation demonstrated a optimistic dose-effect relationship for anti-annexin V IgM with VOC, with elevated VOC danger seen with elevated antibody titers.
Multivariate logistic regression analyses confirmed the affiliation of anti-annexin V IgM, extra so than IgG, as an unbiased VOC danger issue. Anti-annexin V IgG antibodies correlated positively with VOC kind and negatively with HbF and age of VOC onset, whereas anti-annexin V IgM correlated positively with VOC kind, length, frequency, web site, ache severity, hospitalization, and medicine, and negatively with age of VOC onset and HbS ranges. Excessive ranges of anti-annexin V IgM antibodies represent a danger issue for VOC in SCA sufferers.
|
Custom Antibody titration by ELISA up to 2 rabbits and 1 bleed |
|
ELISA-1 |
|
Beta2-Microglobulin ELISA kit ELISA Kit |
|
LF-EK60047 |
|
Chicken thrombomodulin,TM ELISA KIT ELISA |
|
QY-E80092 |
Scientific significance of serum anti-annexin V antibodies in Egyptian sufferers with scleroderma.
The pathogenesis of scleroderma encompasses vascular, immunological, and fibrotic processes, which contribute to medical manifestations. We investigated the prevalence of anti-annexin V IgG and IgM antibodies in sera of scleroderma sufferers and their relation to the presence of different antibodies and improvement of illness morbidity.
Sera of 40 scleroderma sufferers and 15 wholesome controls have been examined for IgG and IgM anti-annexin V antibodies by ELISA and anticentromere antibodies by oblique immunofluorescence. Serum stage of anti-annexin V IgG antibodies in scleroderma sufferers was considerably larger than that of the management (P < 0.001) and correlated considerably with the presence of digital ischemia (P = 0.023) and pulmonary fibrosis (P = 0.02).
IgM isotype was comparable between sufferers and controls (P = 0.317). Anticentromere antibodies are extra prevalent within the restricted cutaneous subtype (P = 0.017). In conclusion, measurement of serum anti-annexin V IgG antibodies in scleroderma sufferers could also be necessary for early prognosis of vascular and pulmonary issues.
Induction of apoptosis by cross-linking antibodies certain to human B-lymphoma cells: expression of Annexin V binding websites on the antibody cap.
There are lots of reviews that cross-linking antibodies (Abs) certain to the floor of B-lymphoma cells can induce apoptosis and/or cell dying, particularly with anti-CD20 Abs. This research was supposed to increase our understanding of those results. To find out if CD20 is a novel goal on this respect, or whether or not Abs to different antigens would have comparable results, six Abs have been examined, with and with out cross-linking with a secondary Ab, on three goal cell strains.
We utilized assays that distinguish between apoptotic, lifeless, and viable cells. Two assays have been used: Annexin V plus propidium iodide, and JC-1 plus SYTOX inexperienced (Molecular Probes, Eugene, OR). A lot of the Abs examined induced a low stage of apoptosis and cell dying in Ramos cells, however not within the different two cell strains (Raji and RL).
On the whole, the extent of toxicity was correlated with the extent of antigen expression, with Abs to high-density antigens having the strongest results. Nevertheless, because the majority of Ramos cells continued to multiply, it’s questionable whether or not toxicity at this stage can present a big medical profit. Unexpectedly, there was additionally a inhabitants of cells that stained weakly with Annexin V.
These cells have been distinct from classical apoptotic cells, and appeared to belong to the viable cell inhabitants. In these cells, Annexin V stained the area of the Ab cap, in distinction to the ringed staining of classical apoptotic cells.
Antibodies to beta2-glycoprotein I and annexin V in ladies with early and late idiopathic recurrent spontaneous abortions.
Anti-phospholipid antibodies (APA) are heterogeneous group of autoantibodies that concentrate on phospholipid or phospholipid-binding proteins. APAs have been beforehand proven to induce a number of thrombotic states, together with idiopathic recurrent spontaneous abortion (RSA). Not like the contribution of the classical lupus anticoagulant (LAC) and anticardiolipin antibodies (ACA), the contribution of anti-beta2 glycoprotein 1 (beta2GPI) and anti-annexin V antibodies to RSA danger stay poorly understood.
We assessed anti-beta2GPI and anti-annexin V IgM and IgG antibodies as RSA danger elements for RSA in 172 Tunisian ladies with >three consecutive idiopathic being pregnant losses, along with 173 matched management ladies. The prevalence of anti-beta2GPI IgG (P=0.41, OR=1.64) and IgM (P=0.50, OR=1.70) have been comparable between instances and controls.
 Annexin V Antibody |
|
3357-100 |
Biovision |
each |
EUR 464.4 |
Annexin V Antibody |
|
3357-30T |
Biovision |
each |
EUR 175.2 |
 Annexin V Polyclonal Antibody |
|
27222-100ul |
SAB |
100ul |
EUR 302.4 |
Annexin V Polyclonal Antibody |
|
27222-50ul |
SAB |
50ul |
EUR 224.4 |
 Antibody) Annexin V (ANXA5) Antibody |
|
abx038319-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
|
Annexin V (ANXA5) Antibody |
|
20-abx001443 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
Annexin V (ANXA5) Antibody |
|
20-abx121016 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
Annexin V (ANXA5) Antibody |
|
20-abx109257 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Annexin V (ANXA5) Antibody |
|
20-abx109540 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Annexin V (ANXA5) Antibody |
|
20-abx110998 |
Abbexa |
|
|
|
|
Annexin V (ANXA5) Antibody |
|
abx032878-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Annexin V (ANXA5) Antibody |
|
abx032878-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Annexin V (ANXA5) Antibody |
|
abx032879-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Annexin V (ANXA5) Antibody |
|
abx032879-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Annexin V (ANXA5) Antibody |
|
abx037408-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
|
Annexin V (ANXA5) Antibody |
|
abx230436-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Annexin V (ANXA5) Antibody |
|
abx230437-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Annexin V (ANXA5) Antibody |
|
abx414511-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
|
Annexin V (ANXA5) Antibody |
|
abx412125-01mg |
Abbexa |
0.1 mg |
EUR 1078.8 |
|
|
 Annexin V Conjugated Antibody |
|
C49376 |
SAB |
100ul |
EUR 476.4 |
 anti- Annexin V antibody |
|
FNab00436 |
FN Test |
100µg |
EUR 606.3 |
|
|
|
Description: Antibody raised against Annexin V |
anti- Annexin V antibody |
|
FNab00437 |
FN Test |
100µg |
EUR 606.3 |
|
|
|
Description: Antibody raised against Annexin V |
anti- Annexin V antibody |
|
FNab09988 |
FN Test |
100µg |
EUR 658.5 |
|
|
|
Description: Antibody raised against Annexin V |
 Annexin V, CF770 |
|
29046 |
Biotium |
25ug |
EUR 410.4 |
|
Description: Minimum order quantity: 1 unit of 25ug |
 Annexin V, CF790 |
|
29047 |
Biotium |
25ug |
EUR 439.2 |
|
Description: Minimum order quantity: 1 unit of 25ug |
Increased anti-annexin V IgG (P=0.02, OR=5.28), however not IgM (P=0.25, OR=1.78), ranges have been seen in instances. Regression evaluation confirmed that anti-beta2GPI IgM (OR=8.90; 95% CI=1.23-64.63) was related to early RSA, whereas anti-annexin V IgG (OR=9.35, 95% CI=1.44-60.86) was related to late RSA. For mixed early + late RSA, the one variable chosen was BMI (OR=0.93; 95% CI=0.87-0.99), and neither anti-annexin V nor anti-beta2GPI IgM and IgG have been related to early + late RSA. Anti-annexin V and anti-beta2GPI seem like unbiased danger markers of RSA.
